
CLAIMS

What is claimed is:

1. A compound of structural Formula I



$\bullet (M)_a \bullet (H_2O)_b$

(I)

or a polymorph thereof, wherein:

a is about 1.0;

b is a fractional or whole number between about 0 and 10, inclusive; and

M is hydrochloric acid.

2. The compound of claim 1, characterized by the presence of four or more peaks with d-spacings of about 14.1, 12.9, 10.1, 8.8, 8.5, 6.5, 5.5, 5.1, 4.8, and 4.4 Å.

3. The compound of claim 2, characterized by the presence of six or more peaks with d-spacings of about 14.1, 12.9, 10.1, 8.8, 8.5, 6.5, 5.5, 5.1, 4.8, and 4.4 Å.

4. The compound of claim 3, characterized by the presence of eight or more peaks with d-spacings of about 14.1, 12.9, 10.1, 8.8, 8.5, 6.5, 5.5, 5.1, 4.8, and 4.4 Å.

5. The compound of claim 1, characterized by the presence of four or more peaks with d-spacings of about 16.5, 14.5, 10.5, 9.1, 8.3, 7.8, 7.6, 5.2, 4.7, and 4.1 Å.

6. The compound of claim 5, characterized by the presence of six or more peaks with d-spacings of about 16.5, 14.5, 10.5, 9.1, 8.3, 7.8, 7.6, 5.2, 4.7, and 4.1 Å.

7. The compound of claim 6, characterized by the presence of eight or more peaks with d-spacings of about 16.5, 14.5, 10.5, 9.1, 8.3, 7.8, 7.6, 5.2, 4.7, and 4.1 Å.

8. A compound as recited in any of claims 1-7 for use as a medicament.

9. A compound as recited in any of claims 1-7 for use in the treatment of a disease.

10. A compound as recited in any of claims 1-7 for use in the manufacture of a medicament for the prevention or treatment of a disease.

11. A pharmaceutical composition comprising a compound as recited in any of claims 1-7 together with a pharmaceutically acceptable carrier.

12. Use of a therapeutically effective amount of the compound as recited in any of claims 1-7 in the manufacture of a medicament for treating an infectious disease in a patient in need thereof.

13. Use of a therapeutically effective amount of the compound as recited in any of claims 1-7 in the manufacture of a medicament for treating an infectious disease, by co-administration with another therapeutic agent.

14. The use as recited in either one of claims 12 and 13 wherein said infectious disease is anthrax.

15. The use as recited in either one of claims 12 and 13 wherein said infectious disease is malaria.

16. The use as recited in either one of claims 12 and 13 wherein said infectious disease is caused by a bacterium.

17. The use as recited in any of claims 12 and 13 wherein said infectious disease is caused by a protozoan.

18. Use of a therapeutically effective amount of the compound as recited in any of claims 1-7 in the manufacture of a medicament for achieving an effect in a patient, wherein the effect is chosen from:
    reducing microbial level(s);
    increasing the rate of microbial killing;
    decreasing the minimal dose for cure; and
    decreasing the duration of time required for cure.

19. The use as recited in claim 18, wherein the microbe is a bacterium.

20. The use as recited in claim 18, wherein the microbe is a protozoan.

21. The use as recited in any of claims 16 and 19, wherein the bacterium is chosen from *Bacteroides*, including, for example, *B. tectum*; *Corynebacterium*; *Chlamydia*, including, for example, *C. pneumoniae* and *C. trachomatis*; *Eikenella*, including, for example, *E. corrodens*; *Enterobacteriaceae*; *Fusobacterium*, including, for example, *F. nucleatum*; *Haemophilus*, including, for example, *H. influenzae*; *Leigonella*, including, for example, *L. pneumophila; Moraxella*, including, for example, *M. catarrhalis*; *Mycobacterium*, including, for example, *M. avium, M. intracellulare*, *M. chimaera*, *M. kansasii*, *M. malmoense*, *M. xenopi*, *M.abscessus*, *M. fortuitum* complex, and *M. chelonae*; *Mycoplasma*, including, for example, *M. hominis*, *M. genitalium*, and *M. pneumoniae*; *Neisseria*, including, for example, *N. gonorrhoeae*; *Pasturella*, including, for example, *P. septica* and *P. multocida*; *Peptostreptococcus*, including, for example, *P. magnus* and *P. micros*; *Prevotella*, including, for example, *P. melaninogenica* and *P. heparinolytica*; *Porphyromonas*; *Propionibacterium*; *Staphylococcus*, including, for example, *S. aureus*; *Streptococcus*, including, for example, *S. pneumoniae*; *Ureaplasma*, including, for example, *U. urealyticum* and *U. parvum*; and *Veillonella*.

22. The use as recited in as recited in either one of claims 17 and 20, wherein the protozoan is chosen from *Cryptosporidium*; *Coccidia*; *Plasmodium*; *Toxoplasma*; *Babesia*; and *Neospora*.

23. The use as recited in claim 22, wherein the protozoan is *Toxoplasma gondii*.

24. The use as recited in claim 22, wherein the protozoan is a *Plasmodium* species.

25. The use as recited in claim 24, wherein the *Plasmodium* is chosen from *P. falciparum*, *P. vivax*, *P. ovale*, *P. malariae*, and *P. knowlesi*.

26. The use as recited in claim 25, wherein the *Plasmodium* is *P. falciparum*.

27. The compound as recited in claim 1, wherein b is about 2.5.